Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: *jx9jn0*_ga*MTE1NzYxMzg0NC4xNjYxNTg2ODk0*_ga_T874FCJ3LG*MTY2MTYyMTE0My4xMC4xLjE2NjE2MjExOTMuMC4wLjA.&utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-6605&utm_content=esc_mackenzie

Prof Isla S Mackenzie (University of Dundee, UK) reveals the findings of the ALL-HEART study, which aimed to evaluate the use of xanthine oxidase inhibitor, allopurinol- a drug reducing the production of uric acid-in patients over 60 with ischemic heart disease (IHD).

5,215 patients were included in the trial, and were randomized to receive either 600mg of allopurinol in addition to their usual medications, or placebo. Participants were then monitored across four years to evaluate the number of cardiovascular events, stroke, and death that occurred.

Questions:

-What is the rationale for studying allopurinol's use in the treatment of IHD, based on its mechanism of action?
-What was the study design and key findings from the trial?
-How do these findings impact clinical practice?/ What are the benefits of implementing allopurinol in clinical practice as a treatment for IHD?
-What were the challenges in this study?
-What further research is needed into allopurinol? What are the next steps for the ALL-HEART Team based on these findings?

Recorded onsite at ESC 22, Barcelona.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "ESC 2022: The ALL-HEART Trial: Allopurionol in the Treatment of Ischaemic Heart Disease" передвинте ползунок вправо